Why, you ask, is it important to pursue the advance of 21^st century regulatory science?

 

Rare Sharing of Data Leads to Progress on Alzheimer’s Disease

By

GINA KOLATA

 

In 2003, a group of scientists and executives from the

 

National Institutes of Health, the Food and Drug Administration, the drug and medical-imaging industries, universities and nonprofit groups joined in a project that experts say had no precedent: a collaborative effort to find the biological markers that show the progression of Alzheimer’s disease in the human brain.

The complete New York Times story can be found

here.

Fund Reagan/Udall now!